|
1
|
Michalski JE and Schwartz DA: Genetic risk
factors for idiopathic pulmonary fibrosis: Insights into
immunopathogenesis. J Inflamm Res. 13:1305–1318. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Churg A: Centrilobular fibrosis in
fibrotic (Chronic) hypersensitivity pneumonitis, usual interstitial
pneumonia, and connective tissue disease-associated interstitial
lung disease. Arch Pathol Lab Med. 144:1509–1516. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jain R, Yadav D, Puranik N, Guleria R and
Jin JO: Sarcoidosis: Causes, diagnosis, clinical features, and
treatments. J Clin Med. 9(1081)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Meyer KC: Pulmonary fibrosis, part I:
Epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med.
11:343–359. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ballester B, Milara J and Cortijo J:
Mucins as a new frontier in pulmonary fibrosis. J Clin Med.
8(1447)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Stock CJW and Renzoni EA: Telomeres in
interstitial lung disease. J Clin Med. 10(1384)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Snijder J, Peraza J, Padilla M, Capaccione
K and Salvatore MM: Pulmonary fibrosis: A disease of alveolar
collapse and collagen deposition. Expert Rev Respir Med.
13:615–619. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Schwartz DA: Idiopathic pulmonary fibrosis
is a genetic disease involving mucus and the peripheral airways.
Ann Am Thorac Soc. 15 (Suppl):S192–S197. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Barros A, Oldham J and Noth I: Genetics of
idiopathic pulmonary fibrosis. Am J Med Sci. 357:379–383.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Walters GI: Occupational exposures and
idiopathic pulmonary fibrosis. Curr Opin Allergy Clin Immunol.
20:103–111. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang L, Ikegami M, Korfhagen TR,
McCormack FX, Yoshida M, Senior RM, Shipley JM, Shapiro SD and
Whitsett JA: Neither SP-A nor NH2-terminal domains of SP-A can
substitute SP-D in regulation of alveolar homeostasis. Am J Physiol
Lung Cell Mol Physiol. 291:L181–L190. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Froidure A, Marchal-Duval E, Homps-Legrand
M, Ghanem M, Justet A, Crestani B and Milleux C: Chaotic activation
of developmental signalling pathways drives idiopathic pulmonary
fibrosis. Eur Respir Rev. 29(190140)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Noth I, Zhang Y, Ma SF, Flores C, Barber
M, Huang Y, Broderick SM, Wade MS, Hysi P, Scuirba J, et al:
Genetic variants associated with idiopathic pulmonary fibrosis
susceptibility and mortality: A genome-wide association study.
Lancet Respir Med. 1:309–317. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Aquino-Galvez A, Camarena A, Montaño M,
Juarez A, Zamora AC, González-Avila G, Checa M, Sandoval-López G,
Vargas-Alarcon G, Granados J, et al: Transporter associated with
antigen processing (TAP) 1 gene polymorphisms in patients with
hypersensitivity pneumonitis. Exp Mol Pathol. 84:173–177.
2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hanalioglu D, Ayvaz DC, Ozgur TT, van der
Burg M, Sanal O and Tezcan I: A novel mutation in TAP1 gene leading
to MHC class I deficiency: Report of two cases and review of the
literature. Clin Immunol. 178:74–78. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
1000 Genome Project: https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes,
visited on 14-Mar-2020.
|
|
17
|
Cho YA and Kim J: Association of IL4,
IL13, and IL4R polymorphisms with gastrointestinal cancer risk: A
meta-analysis. J Epidemiol. 27:215–220. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yoshimoto T: The hunt for the source of
primary interleukin-4: How we discovered that natural killer T
cells and basophils determine T helper type 2 cell differentiation
in vivo. Front Immunol. 9(716)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gieseck RL III, Wilson MS and Wynn TA:
Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol.
18:62–76. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Raghu G, Remy-Jardin M, Myers JL, Richeldi
L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SV, Morell F,
et al: Diagnosis of idiopathic pulmonary fibrosis. An official
ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care
Med. 198:e44–e68. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kocova E, Vanasek J, Koblizek V, Novosad
J, Elias P, Bartos V and Sterclova M: Scoring of the radiological
picture of idiopathic interstitial pneumonia: A study to verify the
reliability of the method. Acta Radiol Open.
4(2058460115605865)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Macintyre N, Crapo RO, Viegi G, Johnson
DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A,
Enright P, et al: Standardisation of the single-breath
determination of carbon monoxide uptake in the lung. Eur Respir J.
26:720–735. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pellegrino R, Viegi G, Brusasco V, Crapo
RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson
P, Hankinson J, et al: Interpretative strategies for lung function
tests. Eur Respir J. 26:948–968. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wuyts WA, Wijsenbeek M, Bondue B, Bouros
D, Bresser P, Robalo Cordeiro C, Hilberg O, Magnusson J, Manali ED,
Morais A, et al: Idiopathic pulmonary fibrosis: Best practice in
monitoring and managing a relentless fibrotic disease. Respiration.
99:73–82. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Vasakova M, Sterclova M, Matej R, Olejar
T, Kolesar L, Skibova J and Striz I: IL-4 polymorphisms, HRCT score
and lung tissue markers in idiopathic pulmonary fibrosis. Hum
Immunol. 74:1346–1351. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kishore A, Žižková V, Kocourková L and
Petřek M: A dataset of 26 candidate gene and pro-inflammatory
cytokine variants for association studies in idiopathic pulmonary
fibrosis: Frequency distribution in normal Czech population. Front
Immunol. 6(476)2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sikorova K, Kishore A, Rapti A, Adam K,
Kocourkova L, Zizkova V, Charikiopoulou M, Kalianos A, Bouros E,
Bouros D and Petrek M: Association of TGF-β3 and ANXA11 with
pulmonary sarcoidosis in Greek population. Expert Rev Respir Med.
14:1065–1069. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Collard HR, Ryerson CJ, Corte TJ, Jenkins
G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM,
et al: Acute exacerbation of idiopathic pulmonary fibrosis. An
international working group report. Am J Respir Crit Care Med.
194:265–75. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Taha N, D'Amato D, Hosein K, Ranalli T,
Sergiacomi G, Zompatori M and Mura M: Longitudinal functional
changes with clinically significant radiographic progression in
idiopathic pulmonary fibrosis: Are we following the right
parameters? Respir Res. 21(119)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Nathan N, Giraud V, Picard C, Nunes H,
Dastot-Le Moal F, Copin B, Galeron L, De Ligniville A, Kuziner N,
Reynaud-Gaubert M, et al: Germline SFTPA1 mutation in familial
idiopathic interstitial pneumonia and lung cancer. Hum Mol Genet.
25:1457–1467. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Deng Y, Li Z, Liu J, Wang Z, Cao Y, Mou Y,
Fu B, Mo B, Wei J, Cheng Z, et al: Targeted resequencing reveals
genetic risks in patients with sporadic idiopathic pulmonary
fibrosis. Hum Mutat. 39:1238–1245. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Juarez I, Gutierrez A, Vaquero-Yuste C,
Molanes-López EM, López A, Lasa I, Gómez R and Martin-Villa JM:
TGFB1 polymorphisms and TGF-β1 plasma levels identify gastric
adenocarcinoma patients with lower survival rate and disseminated
disease. J Cell Mol Med. 25:774–783. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhu L, Wang L, Luo X, Zhang Y, Ding Q,
Jiang X, Wang X, Pan Y and Chen Y: Tollip, an intracellular
trafficking protein, is a novel modulator of the transforming
growth factor-β signaling pathway. J Biol Chem. 287:39653–3963.
2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kaur A, Mathai SM and Schwartz DA:
Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis,
and treatment. Front Med (Lausanne). 4(154)2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gadola SD, Moins-Teisserenc HT, Trowsdale
J, Gross WL and Cerundolo V: TAP deficiency syndrome. Clin Exp
Immunol. 121:173–178. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Qiu B, Huang B, Wang X, Liang J, Feng J,
Chang Y and Li D: Association of TAP1 and TAP2 polymorphisms with
the outcome of persistent HBV infection in a northeast Han Chinese
population. Scand J Gastroenterol. 47:1368–1374. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Biondini D, Cocconcelli E, Bernardinello
N, Lorenzoni G, Rigobello C, Lococo S, Castelli G, Baraldo S, Cosio
MG, Gregori D, et al: Prognostic role of MUC5B rs35705950 genotype
in patients with idiopathic pulmonary fibrosis (IPF) on
antifibrotic treatment. Respir Res. 22(98)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Peljto AL, Zhang Y, Fingerlin TE, Ma SF,
Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd
JE, et al: Association between the MUC5B promoter polymorphism and
survival in patients with idiopathic pulmonary fibrosis. JAMA.
309:2232–2239. 2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Seibold MA, Wise AL, Speer MC, Steele MP,
Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong
SD, et al: A common MUC5B promoter polymorphism and pulmonary
fibrosis. N Engl J Med. 364:1503–1512. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Jiang H, Hu Y, Shang L, Li Y, Yang L and
Chen Y: Association between MUC5B polymorphism and susceptibility
and severity of idiopathic pulmonary fibrosis. Int J Clin Exp
Pathol. 8:14953–14958. 2015.PubMed/NCBI
|
|
41
|
Molyneaux PL, Cox MJ, Willis-Owen SA,
Mallia P, Russell KE, Russell AM, Murphy E, Johnston SL, Schwartz
DA, Wells AU, et al: The role of bacteria in the pathogenesis and
progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care
Med. 190:906–913. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Luzina IG, Lockatell V, Todd NW, Highsmith
K, Keegan AD, Hasday JD and Atamas SP: Alternatively spliced
variants of interleukin-4 promote inflammation differentially. J
Leukoc Biol. 89:763–770. 2011.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Luzina IG, Keegan AD, Heller NM, Rook GA,
Shea-Donohue T and Atamas SP: Regulation of inflammation by
interleukin-4: A review of ‘alternatives’. J Leukoc Biol.
92:753–764. 2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Dressen A, Abbas AR, Cabanski C, Reeder J,
Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J,
Reeder J, et al: Analysis of protein-altering variants in
telomerase genes and their association with MUC5B common variant
status in patients with idiopathic pulmonary fibrosis: A candidate
gene sequencing study. Lancet Respir Med. 6:603–614.
2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Huang Y, Ma SF, Vij R, Oldham JM,
Herazo-Maya J, Broderick SM, Strek ME, White RW, Hogarth DK, Sandbo
NK, et al: A functional genomic model for predicting prognosis in
idiopathic pulmonary fibrosis. BMC Pulm Med. 15(147)2015.PubMed/NCBI View Article : Google Scholar
|
